

Market snapshot



Equities - India	Close	Chg .%	CYTD.%
Sensex	72,102	0.1	-0.2
Nifty-50	21,839	0.1	0.5
Nifty-M 100	45,920	0.0	-0.6
Equities-Global	Close	Chg .%	CYTD.%
S&P 500	5,225	0.9	9.5
Nasdaq	16,369	1.3	9.0
FTSE 100	7,737	0.0	0.1
DAX	18,015	0.2	7.5
Hang Seng	5,804	0.4	0.6
Nikkei 225	40,004	0.0	19.5
Commodities	Close	Chg .%	CYTD.%
Brent (US\$/Bbl)	85	-2.1	10.1
Gold (\$/OZ)	2,186	1.3	6.0
Cu (US\$/MT)	8,819	-0.6	4.2
Almn (US\$/MT)	2,223	0.2	-5.2
Currency	Close	Chg .%	CYTD.%
USD/INR	83.2	0.2	0.0
USD/EUR	1.1	0.5	-1.1
USD/JPY	151.3	0.3	7.2
YIELD (%)	Close	1MChg	CYTD chg
10 Yrs G-Sec	7.1	-0.01	-0.1
10 Yrs AAA Corp	7.6	0.02	-0.2
Flows (USD b)	20-Mar	MTD	CYTD
FII	-0.3	6.71	-2.7
DII	0.32	1.87	6.3
Volumes (INRb)	20-Mar	MTD*	YTD*
Cash	863	1051	1203
F&O	6,87,423	3,75,038	3,98,329

Note: Flows, MTD includes provisional numbers.

*Average



Today's top research idea

Reliance Industries: Turning New Energy Vision to action

- ❖ The Ministry of New and Renewable Energy (MNRE) recently announced its plans to (1) set up two hydrogen hubs in India by FY26, and (2) provide incentives up to INR44.4b for electrolyzer manufacturing through a second tranche. We believe both these announcements are key milestones toward the government's vision to develop a robust green hydrogen eco-system in India. These initiatives also align with RIL's plans to establish a Giga-scale electrolyzer manufacturing facility.
- ❖ Additionally, O2C earnings in 4QFY24 should remain robust, given sharp recovery in SG GRM to USD 7.4/bbl (3QFY24: USD 5.5/bbl) even as key petchem spreads over naphtha are stable on a QoQ basis.
- ❖ In the telecom business, we are building in 5%/4% CAGR for subs/ARPU over FY24-26 period, while in retail, we expect a 29% CAGR EBITDA (FY24-26), led by store additions, higher store productivity, and foray into digital and new commerce. We reiterate our BUY rating on the stock with a TP of INR3,210.




Research covered

Cos/Sector	Key Highlights
Reliance Industries	Turning New Energy Vision to action
Gland Pharma	Performance in revival mode; valuation attractive




Chart of the Day: Reliance Industries (Turning New Energy Vision to action)

Standalone PAT profile



Data as on FY23, Source: Company, MOFSL

Return ratios to improve going forward



Data as on FY23, Source: Company, MOFSL

Research Team (Gautam.Duggad@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.



Kindly click on textbox for the detailed news link

1

US Fed leaves key lending rate unchanged, officials still see three rate cuts this year

The Fed's decision to keep its key lending rate between 5.25 percent and 5.50 percent lets policymakers "carefully assess incoming data, the evolving outlook, and the balance of risks," the central bank said in a statement.

2

Semiconductor manufacturing will put Assam on global map, says Ratan Tata

Tata Semiconductor Assembly and Test Pvt Ltd will set up a semiconductor unit in Assam. With a capacity of producing 48 million chips per day, this facility is being built for Rs 27,000 crore

3

Strong demand for executives in pharma CEO, COO, CLO roles; CTC on offer: Rs 1.75-2.50 crore

Some of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded Sekhmet Pharmaventures, and Carlyle-backed Viyash Lifesciences and Sequent Scientific (animal API manufacturer).

4

5G users in India consume 3.6x more data compared to 4G users: Nokia MBit report

5G users in India are consuming 3.6 times more mobile data as compared to 4G users since its rollout in October 2022, according to a report by telecom gear maker Nokia. In the report titled 'Mobile Broadband Index', released on Wednesday.

5

Strong demand for executives in pharma CEO, COO, CLO roles; CTC on offer: Rs 1.75-2.50 crore

Some of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded Sekhmet Pharmaventures, and Carlyle-backed Viyash Lifesciences and Sequent Scientific (animal API manufacturer).

6

Ramky Infra enters into two contracts worth Rs 216.65 crore for reclamation of Kodungaiyur dumping ground in Chennai

The two orders, Ramky Infrastructure said, are for a total consideration of Rs 39.88 crore and Rs 176.77 crore (exclusive of GST).

7

Jupiter Wagons approves acquisition of 94.25% stake in Bonatrans India for Rs 271 crore

The indicative time period for completion of the acquisition, it said, is 30 days. The acquisition is aimed at meeting the captive requirement of the Jupiter Wagons Limited and to cater evolving demand in the domestic and export market.



Reliance Industries

BSE Sensex 72,102 S&P CNX 21,839

CMP: INR2,888 TP: INR3,210 (+11%) Buy



Stock Info

Bloomberg	RELIANCE IN
Equity Shares (m)	6766
M.Cap.(INRb)/(USDb)	19537.1 / 234.9
52-Week Range (INR)	3025 / 1986
1, 6, 12 Rel. Per (%)	0/11/15
12M Avg Val (INR M)	16523
Free float (%)	50.9

Standalone Financials Snapshot (INR b)

Y/E March	FY24E	FY25E	FY26E
Sales	5,247	5,522	5,612
EBITDA	741	807	880
Adj. PAT	408	478	539
Adj. EPS (INR)	63.3	74.2	83.7
BV/Sh.(INR)	876	946	1,024

Ratios

Net D:E	0.3	0.3	0.2
RoE (%)	7.8	8.5	8.9
RoCE (%)	7.1	7.7	8.0
Payout (%)	10.7	10.7	10.7

Valuations


P/E (x)	45.6	38.9	34.5
P/BV (x)	3.3	3.1	2.8
EV/EBITDA (x)	27.4	24.9	22.6
Div. Yield (%)	0.2	0.3	0.3
FCF per share	7.7	60.9	55.7

Shareholding pattern (%)

As On	Dec-23	Sep-23	Dec-22
Promoter	49.1	49.1	49.1
DII	16.4	15.8	15.0
FII	24.0	24.4	25.6
Others	10.5	10.5	10.3

FII Includes depository receipts

Stock's performance (one-year)



Turning New Energy Vision to action

- The Ministry of New and Renewable Energy (MNRE) recently announced its plans to (1) set up two hydrogen hubs in India by FY26, and (2) provide incentives up to INR44.4b for electrolyzer manufacturing through a second tranche. We believe both these announcements are key milestones toward the government's vision to develop a robust green hydrogen eco-system in India. These initiatives also align with RIL's plans to establish a Giga-scale electrolyzer manufacturing facility.
- Additionally, O2C earnings in 4QFY24 should remain robust, given sharp recovery in SG GRM to USD 7.4/bbl (3QFY24: USD 5.5/bbl) even as key petchem spreads over naphtha are stable on a QoQ basis.
- In the telecom business, we are building in 5%/4% CAGR for subs/ARPU over FY24-26 period, while in retail, we expect a 29% CAGR EBITDA (FY24-26), led by store additions, higher store productivity, and foray into digital and new commerce. We reiterate our BUY rating on the stock with a TP of INR3,210.

Policy support to build Green Hydrogen eco-system continues

- MNRE recently announced guidelines to set up two hydrogen hubs in India by FY26, entailing a capex of INR2b and with the aim to develop demand and supply centers in the same cluster, achieve economies of scale, and increase competitiveness v/s fossil fuels. Central, state, and local governments will come together to develop these hydrogen hubs.
- MNRE also announced guidelines to provide additional incentives for Electrolyzer Manufacturing (Tranche-II). The program is scheduled to run from FY26 to FY30, entailing an outlay of INR 44.4b. Tranche-II aims to promote domestic electrolyzer manufacturing capacity development, thus aiming for lower overall cost of hydrogen production.
- SECI would manage the tender, offering financial support per kW starting at INR4,440/kW and decreasing to INR1,480/kW over five years, while prioritizing local value addition and electrolyzer lifespan.

Transitioning New Energy Vision to tangible plans

- Reliance has a vision to invest USD10b in new energy and materials business and the green hydrogen business is a core part of this vision.
- RIL aims to set up a Giga-scale electrolyzer manufacturing facility in Gujarat and targets to begin its transition from Grey to green hydrogen in FY26. In the next decade, RIL has outlined a vision to be able to produce green hydrogen at less than USD1/kg.
- As such, we see recent policy announcements as key steps in the government's efforts to build a robust hydrogen eco-system in India.
- Further, in FY25, RIL is expected to commence operations at its solar PV giga factory and battery pack production, expecting energy savings from FY26. In the medium term, energy costs for the standalone entity may

drop by 30-40%, with plans to expand the PV factory to 20GW (from 10GW) and the energy storage factory to 50GWh (from 5GWh) by CY27.

- India's current rate of renewable energy (RE) capacity installation is only ~12-15GW per annum, while the "ask-rate" to achieve the government's vision of ~500GW in RE capacity by FY30 is ~50-60GW per annum. As such, we continue to see a strong multi-year pathway for RIL's new energy and materials business.

Refining margin remains strong; Petchem bottoming out

- In 4QFY24'td, SG GRM averaged USD7.4/bbl, up from 3QFY24 average of USD5.5/bbl. Gasoline margin has improved 85% QoQ in 4QFY24'td, while diesel margin was at USD16.7/bbl (flat QoQ). PE, PP, and PX margins over Naphtha in 4QFY24'td is +6%/+3%/-1% QoQ at USD392/330/475 per mt
- We build in a 9% CAGR in standalone EBITDA over FY24-26E, driven by higher volumes (no major shutdowns like in FY24), strong refining margin, and a moderate expansion in petrochemical spreads, especially in FY26.
- O2C earnings in 4QFY24 should see the full impact of higher volumes as well as improving spreads. On a full year basis, this would result in robust FCF generation at the standalone level, which in our estimate rises from INR49b in FY24 to INR359b in FY26.

Valuation and view

- We value Reliance Retail's core business at ~35x EV/EBITDA on FY26E and connectivity at ~5x to arrive at our valuation of INR1,759. Reliance Retail's value in RIL share is INR1,547/share (for its 87.9% stake). Our premium valuation multiples capture the opportunity for the rapid expansion of RELIANCE's retail business and the aggressive rollout of digital platforms.
- For RJio, we are building in a CAGR of 11%/15% in revenue/EBITDA over FY24-26. The business is valued at an EV/EBITDA multiple of 12x on FY26E EBITDA. Potential tariff hikes, market share gains from VIL, and opportunities in digital offer an option value of INR130, thereby arriving at a valuation of INR889/share (adjusted for its 66% stake).
- Using SoTP, we value the standalone business at 7.5x Dec'25E EV/EBITDA to arrive at a valuation of INR955/share. We ascribe an equity valuation of INR889/share to RJio and INR1,547/share to Reliance Retail (factoring in the stake sale) as well as INR37/share to the new energy business. We reiterate our BUY rating with a TP of INR3,210.



Gland Pharma

BSE SENSEX 72,102 S&P CNX 21,839



Gland Pharma Limited

Bloomberg	GLAND IN
Equity Shares (m)	164
M.Cap.(INRb)/(USDb)	280.1 / 3.4
52-Week Range (INR)	2196 / 861
1, 6, 12 Rel. Per (%)	-12/-9/18
12M Avg Val (INR M)	961
Free float (%)	42.1

Financials & Valuations (INR b)

Y/E March	FY24E	FY25E	FY26E
Sales	57.3	64.9	71.5
EBITDA	13.9	16.5	18.5
Adj. PAT	8.5	10.8	12.3
EBIT Margin (%)	24.2	25.5	25.9
Adj EPS (INR)	51.8	65.3	74.5
EPS Gr. (%)	2.8	25.9	14.2
BV/Sh. (INR)	535.1	600.4	674.9

Ratios

Net D-E	(0.3)	(0.4)	(0.5)
RoE (%)	10.2	11.5	11.7
RoCE (%)	9.8	10.6	10.8
Payout (%)	-	-	-

Valuations

P/E (x)	34.2	27.1	23.8
EV/EBITDA (x)	19.8	16.0	13.4
Div. Yield (%)	-	-	-
FCF Yield (%)	(3.8)	2.6	5.1
EV/Sales (x)	4.8	4.1	3.5

Shareholding pattern (%)

As On	Dec-23	Sep-23	Dec-22
Promoter	57.9	57.9	57.9
DII	24.2	22.5	23.1
FII	4.0	4.9	4.7
Others	13.9	16.0	14.3

FII Includes depository receipts

CMP: INR1,701 TP: INR2,240 (32%) BUY

Performance in revival mode; valuation attractive

- Gland Pharma (GLAND) has seen an encouraging revival in its business performance in 9MFY24 after a weak FY23.
- The revival in sales in the company's core markets has been driven by new launches and the relaunch of certain products. With the resolution of supply chain issues, we believe that GLAND is expected to clock a 16% CAGR in sales to INR33b compared to a modest 2% sales CAGR over FY22-24.
- The company is also working on new registrations and adding new markets in the ROW segment.
- Further, GLAND is also adding new areas of growth through the M&A and organic routes. We value GLAND at 27x 12M forward earnings to arrive at a TP of INR2,240. Considering a 20% earnings CAGR over FY24-26, significant underperformance on absolute basis (5% appreciation in past 6M) as well as on relative basis (vs. BSE Healthcare Index), and attractive valuation at 24x FY26E EPS, we reiterate our BUY rating on the stock.


Core markets: Back on growth path

- After delivering a strong performance in core markets over FY18-22 (24% sales CAGR), GLAND witnessed significant challenges in FY23.
- Sales were impacted by excess inventory in the system, financial distress of key customer, Athenex, and the re-prioritization of portfolio strategy by another customer. Further, the situation was worsened by supply shortages of stoppers, resulting in an 11% YoY decline in sales in FY23 to INR24b.
- However, the company has seen strong launches (including re-launches) in the past nine months, resulting in 8.5% YoY growth in sales. GLAND has also added new customers. Considering that major issues are now behind, we expect an 11% CAGR in sales over FY24-26 to INR40b in core markets as GLAND has a robust product pipeline.

RoW markets/India: Work-in-progress to revive outlook

- Over FY18-22, RoW sales witnessed a 79% CAGR, led by robust traction in key products. However, during FY23/9MFY24, sales declined 18%/5% YoY due to supply chain issues, shutdown of facilities and reduced sales of low-margin products.
- GLAND is working on new registrations and is adding new markets.
- Accordingly, we expect ROW sales to reach INR6.9b at an 11% CAGR over FY24-26. In FY23, India sales declined 60% YoY due to supply shortages, including products in NLEM, and shutdown of its insulin facility. However, during 9MFY24, India sales revived and grew by 11.4% YoY.
- While GLAND has reiterated that it would reduce investment in the Indian segment however the company would look for some growth opportunities. Accordingly, we expect a 13% CAGR in India sales over FY24-26.

Stock's performance (one-year)



Building more levers to improve growth prospects

- In addition to its base business, GLAND is building additional levers to improve growth prospects. The company has expanded its CDMO offerings in the European market through the Cenexi acquisition.
- Access to niche technologies and a robust customer base would enable GLAND to establish its presence in the CDMO space. Additionally, GLAND has invested in developing capabilities in the biosimilar space to expand differentiated offerings.
- Further, the company continues to file products and has gained access to the China market as well.
- Overall, GLAND has invested INR13b in these new areas of growth so far, which is yet to provide meaningful benefits.

Valuation and view

- We expect GLAND to deliver a 20% earnings CAGR over FY24-26 on the back of superior performance in core markets of US/EU/Canada/Australia and ROW markets, supported by improving Cenexi operations. We value GLAND at 27x 12M forward earnings to arrive at a TP of INR2,240. After YoY earnings decline in FY23 and stable FY24, we expect earnings growth to improve over the next two years. **Reiterate BUY.**

Valuation snapshot

Company	Reco	MCap (USD B)	EPS (INR)			EPS Gr. YoY (%)		PE (x)		EV/EBITDA (x)		ROE (%)		
			FY24E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY24E	FY25E	FY26E
Ajanta Pharma	Buy	3.2	66.5	79.1	92.1	18.9	16.5	26.6	22.8	20.2	18.0	22.8	22.9	22.5
Alembic Pharma	Neutral	2.2	29.0	34.8	39.5	20.0	13.6	26.8	23.6	17.1	14.9	12.3	13.2	13.4
Alkem Lab	Neutral	7.2	164.0	180.9	196.0	10.3	8.4	26.9	24.8	23.6	21.1	20.1	19.1	17.9
Aurobindo Pharma	Neutral	7.2	51.2	60.3	69.4	17.9	15.1	16.4	14.3	8.7	7.7	10.6	11.3	11.6
Biocon	Neutral	3.6	2.1	8.5	13.6	298.1	60.1	28.9	18.0	12.3	10.2	1.4	5.4	8.2
Cipla	Buy	14.4	53.0	57.7	64.4	8.9	11.6	24.9	22.3	15.9	14.1	16.1	15.2	14.7
Divi's Lab.	Neutral	11.2	56.5	77.4	93.8	36.9	21.1	44.5	36.7	32.7	27.5	11.3	14.2	15.5
Dr Reddy's Labs	Neutral	12.7	317.8	322.9	338.8	1.6	4.9	19.0	18.1	11.2	10.1	20.7	17.7	15.9
Eris Lifescience	Neutral	1.4	31.1	32.4	43.2	4.2	33.3	26.2	19.6	10.6	9.2	18.2	16.6	19.2
Gland Pharma	Buy	3.5	51.8	65.3	74.5	25.9	14.2	27.2	23.8	15.5	13.0	10.2	11.5	11.7
Glenmark Pharma	Neutral	3.2	1.5	37.7	45.9	2336.7	21.8	24.4	20.0	11.2	9.5	0.5	10.3	11.4
Glaxosmit Pharma	Neutral	4.0	40.8	43.4	47.1	6.5	8.5	45.0	41.5	33.9	30.6	34.9	32.7	31.0
Granules India	Buy	1.2	18.6	25.6	33.0	37.6	28.9	16.1	12.5	9.5	7.7	14.8	17.5	18.9
Ipca Labs.	Neutral	3.6	22.2	35.5	46.9	60.1	32.2	32.2	24.4	18.1	14.5	9.2	13.3	15.6
Laurus Labs	Buy	2.5	3.9	11.8	15.3	206.5	29.5	32.8	25.3	16.7	14.0	5.0	14.2	16.1
Lupin	Neutral	8.8	42.4	47.2	55.2	11.4	17.0	33.2	28.4	18.6	16.1	14.3	13.9	14.2
Piramal Pharma	Buy	1.9	1.4	3.1	4.8	116.6	56.0	39.4	25.3	14.7	12.2	2.5	4.9	7.2
Sun Pharma.Inds.	Buy	45.4	40.1	47.3	56.6	17.9	19.5	32.8	27.4	25.6	21.3	16.1	16.5	17.1
Torrent Pharma.	Neutral	10.5	48.4	65.4	81.6	35.1	24.7	38.2	30.6	22.0	18.9	22.6	26.7	33.3
Zybus LifeScience	Neutral	12.2	34.4	36.2	36.8	5.1	1.6	26.8	26.4	17.6	16.9	18.2	16.3	14.6

Source: MOFSL, Company



JSW Group: Looking at an investment of \$10 billion in automobile industry in a decade; Sajjan Jindal, Chairman

- Believe that India will go through a transformation in mobility
- Rs. 40k cr. of investment in Odisha will be driven primarily by JSW group
- Looking to aggressively localize in India for Indians and the world

[➔ Read More](#)

Bajaj Auto: Last few quarters are suggesting recovery in exports; Rakesh Sharma, Executive Director

- Need to watch for next couple of quarters in terms of exports
- Have around 20 models serving different sub-segments
- Focus is to expand the portfolio when it comes to Chetak
- Pushing forward hard on network expansion, Chetan would be available in 500+ stores in next few months

[➔ Read More](#)

Tata Power: See double digit growth in power consumption soon; Praveer Sinha, MD & CEO

- See huge capacity addition in India every 10 years
- Will invest Rs. 20k Cr. every year from now
- Expect big announcements post-election on distribution front
- By 2027-2030, we will see a reduction in power prices

[➔ Read More](#)

Symphony: Demand is stable, inventory with dealers is at regular levels; Nrupesh Shah, MD

- Demand trends in southern and eastern parts of India looks decent
- No discount was offered Feb onwards, no further price hikes on the cards
- GM will be better in 4Q vs 3Q
- Continue to maintain 50% market share

[➔ Read More](#)

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- (a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Companies where there is interest
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under

applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemanji Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.